本试验的目的是选择中国健康受试者，以北京星昊医药股份有限公司提供的复方利血平氨苯蝶啶胶囊为受试制剂，按有关BE试验的规定，与国内上市的北京双鹤药业股份有限公司生产的复方利血平氨苯蝶啶片（商品名：0号，参比制剂）进行人体相对生物利用度与生物等效性试验，计算受试制剂的相对生物利用度，比较两种制剂的生物等效性。

[Translation]

The purpose of this study was to select healthy Chinese subjects, use the compound reserpine and triamterene capsules provided by Beijing Xinghao Pharmaceutical Co., Ltd. as the test preparation, and conduct human relative bioavailability and bioequivalence tests on the compound reserpine and triamterene tablets (trade name: No. 0, reference preparation) produced by Beijing Shuanghe Pharmaceutical Co., Ltd. on the domestic market in accordance with the relevant BE test regulations, calculate the relative bioavailability of the test preparation, and compare the bioequivalence of the two preparations.

Start Date08 Apr 2015

Sponsor / Collaborator

Beijing Sunho Pharmaceutical Co., Ltd.

100 Clinical Results associated with NCC x VMAT2

100 Translational Medicine associated with NCC x VMAT2

0 Patents (Medical) associated with NCC x VMAT2

Literatures (Medical) associated with NCC x VMAT2

PLOS ONEQ3 · CROSS-FIELD

Association of high-risk neuroblastoma classification based on expression profiles with differentiation and metabolism

Q3 · CROSS-FIELD

ArticleOA

Author: Sekiguchi, Masahiro ; Seki, Masafumi ; Hoshino, Noriko ; Hiwatarai, Mitsuteru ; Yoshida, Kenichi ; Watanabe, Kentaro ; Takita, Junko ; Suzuki, Hiromichi ; Hayashi, Yasuhide ; Shiozawa, Yusuke ; Miyano, Satoru ; Kimura, Shunsuke ; Oka, Akira ; Isobe, Tomoya ; Ogawa, Seishi

Neuroblastoma, the most common extracranial solid malignancy among children, originates from undifferentiated neural crest cells (NCC). Despite recent intensified treatment, high-risk patients still have a high mortality rate. To explore a new therapeutic strategy, we performed an integrated genomic and transcriptomic analysis of 30 high-risk neuroblastoma cases. Based on the expression profiling of RNA sequencing, neuroblastoma was classified into Mesenchymal (MES; n = 5) and Noradrenergic (ADRN; n = 25) clusters, as previously reported in the super-enhancer landscape. The expression patterns in MES-cluster cases were similar to normal adrenal glands, with enrichment in secretion-related pathways, suggesting chromaffin cell-like features built from NCC-derived Schwann cell precursors (SCPs). In contrast, neuron-related pathways were enriched in the ADRN-cluster, indicating sympathoblast features reported to originate from NCC but not via SCPs. Thus, MES- and ADRN-clusters were assumed to be corresponding to differentiation pathways through SCP and sympathoblast, respectively. ADRN-cluster cases were further classified into MYCN- and ATRX-clusters, characterized by genetic alterations, MYCN amplifications and ATRX alterations, respectively. MYCN-cluster cases showed high expression of ALDH18A1, encoding P5CS related to proline production. As reported in other cancers, this might cause reprogramming of proline metabolism leading to tumor specific proline vulnerability candidate for a target therapy of metabolic pathway. In ATRX-cluster, SLC18A2 (VMAT2), an enzyme known to prevent cell toxicity due to the oxidation of dopamine, was highly expressed and VMAT2 inhibitor (GZ-793A) represented significant attenuation of cell growth in NB-69 cell line (high SLC18A2 expression, no MYCN amplification) but not in IMR-32 cell line (MYCN amplification). In addition, the correlation of VMAT2 expression with metaiodobenzylguanidine (MIBG) avidity suggested a combination of VMAT2 inhibitor and MIBG radiation for a novel potential therapeutic strategy in ATRX-cluster cases. Thus, targeting the characteristics of unique neuroblastomas may prospectively improve prognosis.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis